Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | RAD52 | P43351 | 5/20 | 0.70 |
| ▸ | POLB | P06746 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.62 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.60 |
| ▸ | ACP1 | P24666 | 2/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | PDE5A | O76074 | 2/20 | 0.54 |
| ▸ | TOP2A | P11388 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23723436 | 0.93 | TLR9 (0.72) | MAPK1ALDH1A1RAD52POLBKMT2A | |
| SCHEMBL30125496 | 0.93 | TLR9 (0.72) | MAPK1ALDH1A1RAD52POLBKMT2A | |
| SCHEMBL23747958 | 0.84 | MAPK1 (0.71) | MAPK1ALDH1A1POLBKMT2ATLR9 | |
| SCHEMBL23723245 | 0.81 | PDE5A (0.53) | MAPK1ALDH1A1RAD52POLBKMT2A | |
| SCHEMBL10065464 | 0.81 | ALDH1A1 (0.76) | MAPK1ALDH1A1RAD52POLBKMT2A | |
| Hydrochloric Acid SCHEMBL4511057 | 0.80 | MAPK1 (0.78) | MAPK1ALDH1A1RAD52POLBKMT2A | |
| SCHEMBL26639503 | 0.80 | MAPK1 (0.74) | MAPK1ALDH1A1RAD52POLBKMT2A | |
| SCHEMBL17799977 | 0.79 | GBA1 (0.54) | MAPK1POLBKMT2ATLR9ACP1 | |
| SCHEMBL29713600 | 0.79 | TLR9 (0.95) | MAPK1ALDH1A1RAD52POLBKMT2A | |
| SCHEMBL1085391 | 0.79 | TLR9 (0.95) | MAPK1ALDH1A1RAD52POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | MAPK1 3295/4885ALDH1A1 1908/4885RAD52 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.